Journal: The Cochrane Database of Systematic Reviews

Article Title: Tiotropium versus placebo for chronic obstructive pulmonary disease

doi: 10.1002/14651858.CD009285.pub3

Figure Lengend Snippet: Bateman 2010b

Article Snippet: Short‐acting relief medications were substituted for fenoterol as needed Outcomes Lung function and exacerbations were evaluated by respective pulmonary function tests (spirometry), before (trough value), and 2 hours after inhalation of study medication, FVC, Inspiratory Vital Capacity, and tolerability Notes Funding : Boehringer Ingelheim Study number : Boehringer Ingelheim 205.257, ClinicalTrials.gov NCT00274573 Definitions : exacerbations were defined as a respiratory event which lasted for more than 3 days which required treatment or significant increase in the dose of COPD medication (bronchodilator and/or systemic corticosteroids or treatment with antibiotics) Risk of bias Bias Authors' judgement Support for judgement Random sequence generation (selection bias) Low risk The randomisation list was generated by Boehringer Ingelheim using a validated system, which involved a pseudo‐random number generator so that the resulting treatment sequence was both reproducible and non‐predictable Allocation concealment (selection bias) Low risk All investigational medication for each patient was identified by a unique medication number.

Techniques: Biomarker Discovery, Sequencing, Selection, Generated, Control

Journal: The Cochrane Database of Systematic Reviews

Article Title: Tiotropium versus placebo for chronic obstructive pulmonary disease

doi: 10.1002/14651858.CD009285.pub3

Figure Lengend Snippet: Beeh 2006

Article Snippet: Short‐acting relief medications were substituted for fenoterol as needed Outcomes Lung function and exacerbations were evaluated by respective pulmonary function tests (spirometry), before (trough value), and 2 hours after inhalation of study medication, FVC, Inspiratory Vital Capacity, and tolerability Notes Funding : Boehringer Ingelheim Study number : Boehringer Ingelheim 205.257, ClinicalTrials.gov NCT00274573 Definitions : exacerbations were defined as a respiratory event which lasted for more than 3 days which required treatment or significant increase in the dose of COPD medication (bronchodilator and/or systemic corticosteroids or treatment with antibiotics) Risk of bias Bias Authors' judgement Support for judgement Random sequence generation (selection bias) Low risk The randomisation list was generated by Boehringer Ingelheim using a validated system, which involved a pseudo‐random number generator so that the resulting treatment sequence was both reproducible and non‐predictable Allocation concealment (selection bias) Low risk All investigational medication for each patient was identified by a unique medication number.

Techniques: Infection, Medications, Sequencing, Selection, Generated, Control

Journal: The Cochrane Database of Systematic Reviews

Article Title: Tiotropium versus placebo for chronic obstructive pulmonary disease

doi: 10.1002/14651858.CD009285.pub3

Figure Lengend Snippet: Brusasco 2003

Article Snippet: Short‐acting relief medications were substituted for fenoterol as needed Outcomes Lung function and exacerbations were evaluated by respective pulmonary function tests (spirometry), before (trough value), and 2 hours after inhalation of study medication, FVC, Inspiratory Vital Capacity, and tolerability Notes Funding : Boehringer Ingelheim Study number : Boehringer Ingelheim 205.257, ClinicalTrials.gov NCT00274573 Definitions : exacerbations were defined as a respiratory event which lasted for more than 3 days which required treatment or significant increase in the dose of COPD medication (bronchodilator and/or systemic corticosteroids or treatment with antibiotics) Risk of bias Bias Authors' judgement Support for judgement Random sequence generation (selection bias) Low risk The randomisation list was generated by Boehringer Ingelheim using a validated system, which involved a pseudo‐random number generator so that the resulting treatment sequence was both reproducible and non‐predictable Allocation concealment (selection bias) Low risk All investigational medication for each patient was identified by a unique medication number.

Techniques: Infection, Medications, Sequencing, Selection, Generated, Control

Journal: The Cochrane Database of Systematic Reviews

Article Title: Tiotropium versus placebo for chronic obstructive pulmonary disease

doi: 10.1002/14651858.CD009285.pub3

Figure Lengend Snippet: Freeman 2007

Article Snippet: Short‐acting relief medications were substituted for fenoterol as needed Outcomes Lung function and exacerbations were evaluated by respective pulmonary function tests (spirometry), before (trough value), and 2 hours after inhalation of study medication, FVC, Inspiratory Vital Capacity, and tolerability Notes Funding : Boehringer Ingelheim Study number : Boehringer Ingelheim 205.257, ClinicalTrials.gov NCT00274573 Definitions : exacerbations were defined as a respiratory event which lasted for more than 3 days which required treatment or significant increase in the dose of COPD medication (bronchodilator and/or systemic corticosteroids or treatment with antibiotics) Risk of bias Bias Authors' judgement Support for judgement Random sequence generation (selection bias) Low risk The randomisation list was generated by Boehringer Ingelheim using a validated system, which involved a pseudo‐random number generator so that the resulting treatment sequence was both reproducible and non‐predictable Allocation concealment (selection bias) Low risk All investigational medication for each patient was identified by a unique medication number.

Techniques: Biomarker Discovery, Infection, Sequencing, Selection, Generated

Journal: The Cochrane Database of Systematic Reviews

Article Title: Tiotropium versus placebo for chronic obstructive pulmonary disease

doi: 10.1002/14651858.CD009285.pub3

Figure Lengend Snippet: Johansson 2008

Article Snippet: Short‐acting relief medications were substituted for fenoterol as needed Outcomes Lung function and exacerbations were evaluated by respective pulmonary function tests (spirometry), before (trough value), and 2 hours after inhalation of study medication, FVC, Inspiratory Vital Capacity, and tolerability Notes Funding : Boehringer Ingelheim Study number : Boehringer Ingelheim 205.257, ClinicalTrials.gov NCT00274573 Definitions : exacerbations were defined as a respiratory event which lasted for more than 3 days which required treatment or significant increase in the dose of COPD medication (bronchodilator and/or systemic corticosteroids or treatment with antibiotics) Risk of bias Bias Authors' judgement Support for judgement Random sequence generation (selection bias) Low risk The randomisation list was generated by Boehringer Ingelheim using a validated system, which involved a pseudo‐random number generator so that the resulting treatment sequence was both reproducible and non‐predictable Allocation concealment (selection bias) Low risk All investigational medication for each patient was identified by a unique medication number.

Techniques: Biomarker Discovery, Infection, Sequencing, Selection, Generated, Control

Journal: The Cochrane Database of Systematic Reviews

Article Title: Tiotropium versus placebo for chronic obstructive pulmonary disease

doi: 10.1002/14651858.CD009285.pub3

Figure Lengend Snippet: Magnussen 2008

Article Snippet: Short‐acting relief medications were substituted for fenoterol as needed Outcomes Lung function and exacerbations were evaluated by respective pulmonary function tests (spirometry), before (trough value), and 2 hours after inhalation of study medication, FVC, Inspiratory Vital Capacity, and tolerability Notes Funding : Boehringer Ingelheim Study number : Boehringer Ingelheim 205.257, ClinicalTrials.gov NCT00274573 Definitions : exacerbations were defined as a respiratory event which lasted for more than 3 days which required treatment or significant increase in the dose of COPD medication (bronchodilator and/or systemic corticosteroids or treatment with antibiotics) Risk of bias Bias Authors' judgement Support for judgement Random sequence generation (selection bias) Low risk The randomisation list was generated by Boehringer Ingelheim using a validated system, which involved a pseudo‐random number generator so that the resulting treatment sequence was both reproducible and non‐predictable Allocation concealment (selection bias) Low risk All investigational medication for each patient was identified by a unique medication number.

Techniques: Biomarker Discovery, Sequencing, Selection, Generated, Control

Journal: The Cochrane Database of Systematic Reviews

Article Title: Tiotropium versus placebo for chronic obstructive pulmonary disease

doi: 10.1002/14651858.CD009285.pub3

Figure Lengend Snippet: Niewoehner 2005

Article Snippet: Short‐acting relief medications were substituted for fenoterol as needed Outcomes Lung function and exacerbations were evaluated by respective pulmonary function tests (spirometry), before (trough value), and 2 hours after inhalation of study medication, FVC, Inspiratory Vital Capacity, and tolerability Notes Funding : Boehringer Ingelheim Study number : Boehringer Ingelheim 205.257, ClinicalTrials.gov NCT00274573 Definitions : exacerbations were defined as a respiratory event which lasted for more than 3 days which required treatment or significant increase in the dose of COPD medication (bronchodilator and/or systemic corticosteroids or treatment with antibiotics) Risk of bias Bias Authors' judgement Support for judgement Random sequence generation (selection bias) Low risk The randomisation list was generated by Boehringer Ingelheim using a validated system, which involved a pseudo‐random number generator so that the resulting treatment sequence was both reproducible and non‐predictable Allocation concealment (selection bias) Low risk All investigational medication for each patient was identified by a unique medication number.

Techniques: Biomarker Discovery, Medications, Sequencing, Selection, Generated

Journal: The Cochrane Database of Systematic Reviews

Article Title: Tiotropium versus placebo for chronic obstructive pulmonary disease

doi: 10.1002/14651858.CD009285.pub3

Figure Lengend Snippet: Trooster 2011

Article Snippet: Short‐acting relief medications were substituted for fenoterol as needed Outcomes Lung function and exacerbations were evaluated by respective pulmonary function tests (spirometry), before (trough value), and 2 hours after inhalation of study medication, FVC, Inspiratory Vital Capacity, and tolerability Notes Funding : Boehringer Ingelheim Study number : Boehringer Ingelheim 205.257, ClinicalTrials.gov NCT00274573 Definitions : exacerbations were defined as a respiratory event which lasted for more than 3 days which required treatment or significant increase in the dose of COPD medication (bronchodilator and/or systemic corticosteroids or treatment with antibiotics) Risk of bias Bias Authors' judgement Support for judgement Random sequence generation (selection bias) Low risk The randomisation list was generated by Boehringer Ingelheim using a validated system, which involved a pseudo‐random number generator so that the resulting treatment sequence was both reproducible and non‐predictable Allocation concealment (selection bias) Low risk All investigational medication for each patient was identified by a unique medication number.

Techniques: Medications, Activity Assay, Sequencing, Selection, Generated, Control